Changchun high tech live attenuated herpes zoster vaccine is expected to obtain clinical approval this year

Yang Zhanmin, chairman of Changchun hi tech, said at the 2013 performance presentation meeting that the new drug "live attenuated herpes zoster vaccine" that the company is applying for clinical application is expected to obtain clinical approval this year and enter clinical trials The live attenuated vaccine for herpes zoster was developed by Baike biology, a holding subsidiary of Changchun hi tech, which holds 46.15% of the shares, for the prevention of herpes zoster It belongs to six categories of biological products for prevention Baike biology applied for the clinical approval of the product in May 2012 At present, the domestic enterprises applying for the product also include Changchun Changsheng Biology (live attenuated herpes zoster vaccine) and Beijing Wantai Biology (freeze-dried live attenuated herpes zoster vaccine) Yang Zhanmin said that at present, there is no live attenuated herpes zoster vaccine product on the market in China More than 200 million elderly people in China are potential target population The target population for which the company applies for indications is over 50 years old, with great market potential.